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Abstract
Link and colleagues present a pilot study investigating platelet
function and platelet numbers in patients with cardiogenic shock
and acute kidney failure undergoing continuous venovenous
haemodialysis. Their data indicate a significantly reduced platelet
loss with combined therapy of unfractionated heparin plus tirofiban,
the glycoprotein IIb/IIIa antagonist, compared with unfractionated
heparin therapy alone. Owing to the small sample size, however,
the potential impact of additional treatment variables (antiplatelet
agents, intraaortic counterpulsation) could not be clarified. A
substantially larger, adequately powered study is therefore called
for to establish the potential clinical relevance of these findings.
In a recent article for Critical Care Link and colleagues
reported that the reversible platelet glycoprotein IIb/IIIa antago-
nist tirofiban may prevent platelet activation and preserves
platelet numbers during continuous venovenous haemodialysis
in patients with cardiogenic shock [1].
Acute kidney failure is a frequent complication in the critically
ill, particularly so in patients with severe sepsis/septic shock
or with acute myocardial infarction/cardiogenic shock [2,3].
Often this complication will entail the need for renal replace-
ment therapy until kidney function recovers. Contact of blood
with artificial surfaces of extracorporeal systems, however,
may lead to platelet activation, to formation of platelet–
monocyte aggregates, and to induction of inflammation. In the
majority of cases, extracorporeal therapy thus requires an
effective anticoagulation strategy that, in turn, may put the
patient at risk of bleeding complications. Especially during
continuous renal replacement therapy (CRRT), platelet
dysfunction may occur with increased activation and
aggregation and – ultimately – with platelet loss.
In recent years, glycoprotein IIb/IIIa antagonists have found
their way into clinical routine, serving as powerful receptor
blockers in the final stage of platelet activation; for example,
in patients with acute coronary syndromes and percutaneous
transluminal angioplasty [4-6]. These antagonists have also
been proposed as a pharmacological strategy to prevent
platelet loss during extracorporeal circulation, especially in
cardiac surgery (platelet anaesthesia) [7,8]; however, their
potential role in extracorporeal renal replacement therapies is
unclear at present.
In their pilot study Link and colleagues randomly assigned 40
patients with cardiogenic shock and acute kidney failure
requiring CRRT to two groups, either receiving unfractionated
heparin (UFH) (n = 20) or receiving a combined anticoagula-
tion with UFH and tirofiban (n = 20) [1]. They found in the
group receiving only UFH that the percentage of platelet–
monocyte aggregates was significantly increased (P <0.001)
and the platelet number was significantly decreased
(P <0.001). In contrast, platelet–monocyte aggregates and
the decrement in platelet numbers were significantly reduced
under combined therapy (P <0.001). There were no
significant differences between the groups regarding the
efficacy of CRRT, the haemofilter lifespan, or bleeding events.
Platelet transfusions were only necessary in three patients of
the UFH group (P = 0.016). The authors conclude that, in
patients with cardiogenic shock and acute kidney injury
requiring CRRT, the use of tirofiban in addition to UFH
prevents platelet loss and platelet–monocyte interaction and
may preserve platelet function.
Whilst these findings are of interest and are of potential
clinical relevance, caution needs to be exercised in their
interpretation. As is also reflected in the present study,
patients with acute coronary syndromes and cardiogenic
shock will often be subjected to a variety of specific (pharma-
cological and nonpharmacological) interventions that may
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impact on platelet function and/or number. This includes the
administration of anticoagulants (heparins, heparinoids, throm-
bin inhibitors), antiplatelet agents (glycoprotein IIb/IIIa antago-
nists, acetylsalicylic acid, thienopyridine), and catecholamines
[9], as well as treatment with intraaortic counterpulsation. In a
fairly small and heterogeneous cohort it is not feasible to
dissect out their respective influences on the study out-
comes. The same holds true for the potential influence of the
type and mode of the extracorporeal treatment and materials,
and, last but not least, for the metabolic control/uraemic state
of the patient. Moreover, the response of individual patients to
acetylsalicylic acid and/or thienopyridin may vary con-
siderably up to the point of the new and not completely
understood phenomenon of thienopyridine nonresponders
[10,11], an issue that will also have to be carefully considered
in a subsequent study.
Another finding of the present study may raise concerns. The
platelet numbers in the UFH therapy group were more than
halved, dropping from an average of (216 ± 64.3) × 109/l to
as low as (87.3 ± 41.1) × 109/l within 4 days – three patients
with platelet counts <20 × 109/l even requiring platelet trans-
fusions. Given the fact that the authors used modern poly-
sulphone capillary haemofilters and employed a continuous
venovenous haemodialysis regime that reduces trans-
membrane pressures and thus reduces shear stress
compared with postdilution continuous venovenous haemo-
filtration, the observed extent of platelet loss seems unusually
large and remains unexplained.
In summary, the study by Link and colleagues raises the
important question of whether platelet anaesthesia with
tirofiban prevents platelet activation and loss during CRRT.
The data presented indicate a significantly reduced platelet
loss with additional glycoprotein IIb/IIIa antagonist therapy
compared with UFH therapy alone. Owing to the small
sample size, however, the potential impact of additional
treatment variables could not be clarified. A substantially
larger, adequately powered study is therefore warranted
before these results can be generalized.
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